TY - JOUR
T1 - Current perspectives in the epidemiology and control of lymphatic filariasis
AU - de Souza, Dziedzom K.
AU - Bockarie, Moses J.
N1 - Publisher Copyright:
Copyright © 2025 American Society for Microbiology All Rights Reserved.
PY - 2025/6
Y1 - 2025/6
N2 - Lymphatic filariasis (LF), a debilitating tropical disease caused by parasitic filarial worms, Wuchereria bancrofti, Brugia malayi, and Brugia timori, remains a significant public health challenge in tropical and subtropical settings where the disease is endemic. The disease affects millions worldwide, leading to severe disability and social stigma. Following the World Health Assembly resolution WHA50.29 in 1997 encouraging Member States to eliminate LF as a public health problem, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established in 2000. The establishment of the GPELF paced the way for global eradication efforts, with commitments from non-governmental organizations and Merck donating the drug ivermectin as long as it is needed to control the disease. The advances in the diagnosis and control of LF have shown promising results, including developing novel diagnostic tools, therapeutic agents, and integrated vector management and surveillance strategies. This review explores the latest advances in our understanding of LF epidemiology, transmission assessments, clinical manifestations, and immune response to infection. We further discuss the current state of diagnostic development, treatment approaches, and control measures, highlighting the importance of continued research in the fight against this disease.
AB - Lymphatic filariasis (LF), a debilitating tropical disease caused by parasitic filarial worms, Wuchereria bancrofti, Brugia malayi, and Brugia timori, remains a significant public health challenge in tropical and subtropical settings where the disease is endemic. The disease affects millions worldwide, leading to severe disability and social stigma. Following the World Health Assembly resolution WHA50.29 in 1997 encouraging Member States to eliminate LF as a public health problem, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) was established in 2000. The establishment of the GPELF paced the way for global eradication efforts, with commitments from non-governmental organizations and Merck donating the drug ivermectin as long as it is needed to control the disease. The advances in the diagnosis and control of LF have shown promising results, including developing novel diagnostic tools, therapeutic agents, and integrated vector management and surveillance strategies. This review explores the latest advances in our understanding of LF epidemiology, transmission assessments, clinical manifestations, and immune response to infection. We further discuss the current state of diagnostic development, treatment approaches, and control measures, highlighting the importance of continued research in the fight against this disease.
KW - Wuchereria bancrofti
KW - elephantiasis
KW - lymphatic filariasis
UR - https://www.scopus.com/pages/publications/105008832353
U2 - 10.1128/cmr.00126-23
DO - 10.1128/cmr.00126-23
M3 - Review article
C2 - 40172233
AN - SCOPUS:105008832353
SN - 0893-8512
VL - 38
JO - Clinical Microbiology Reviews
JF - Clinical Microbiology Reviews
IS - 2
ER -